Ångström AI logo

Ångström AI

Gen AI molecular simulations that reproduce wetlab results

Summer 2024Healthcare / Healthcare -> Drug Discovery and DeliverySan Francisco, CA, USA5 employees
AI-powered Drug Discovery
Artificial Intelligence
Biotech
Drug discovery
AI

About

Angstrom AI builds GenAI-based molecular simulations to substitute wet lab experiments in the pre-clinical drug development pipeline. We are a team of 2 PhD's and 2 Professors from the University of Cambridge who decided to start a company together after we realised how to combine breakthoughs in our research in quantum-accurate models of physics and generative AI models. Our Biotech/Pharma clients can verify the efficacy and safety of new drug candidates using our computer simulations, which match the accuracy of wet lab experiments, but are over 100x faster. We achieve this accuracy by constraining our genAI-based simulations to obey the laws of physics, avoiding the hallucinations seen in other GenAI technologies. Since joining YC, Angstrom AI has developed the first physically accurate gen-AI based simulation of multiple molecules interacting. We have published the first molecule water solubility results with accuracy within the error range of wet lab experiments. We have also kicked-off a 150K pilot project with a pharma company to apply our tech to estimating solubility in their drug development pipeline.

Founders (3)

Javier Antoran
Founder
Jose Miguel Hernandez Lobato
Founder
Laurence Midgley
Founder

Details

Status
Active
Stage
Early
Team Size
5
Regions
United States of America, America / Canada, Remote, Partly Remote